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Homozygous p.Ser267Phe in 
SLC10A1 is associated with a 
new type of hypercholanemia 
and implications for personalized 
medicine
Ruihong Liu1, Chuming Chen2,3, Xuefeng Xia4, Qijun Liao5, Qiong Wang6, Paul J. Newcombe7, 
Shuhua Xu  8, Minghui Chen6, Yue Ding9, Xiaoying Li10, Zhihong Liao11, Fucheng Li12, Minlian 
Du13, Huaiqiu Huang14, Ruimin Dong15, Weiping Deng16, Ye Wang17, Binghui Zeng18, Qihao 
Pan19, Danhua Jiang20, Hao Zeng20, Pak Sham21,22,23,24, Yingnan Cao25, Patrick H. Maxwell26, 
Zhi-liang Gao2,3, Liang Peng2,3 & Yiming Wang1,20,25
SLC10A1 codes for the sodium-taurocholate cotransporting polypeptide (NTCP), which is a 
hepatocellular transporter for bile acids (BAs) and the receptor for hepatitis B and D viruses. NTCP 
is also a target of multiple drugs. We aimed to evaluate the medical consequences of the loss of 
function mutation p.Ser267Phe in SLC10A1. We identified eight individuals with homozygous 
p.Ser267Phe mutation in SLC10A1 and followed up for 8–90 months. We compared their total 
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serum BAs and 6 species of BAs with 170 wild-type and 107 heterozygous healthy individuals. We 
performed in-depth medical examinations and exome sequencing in the homozygous individuals. 
All homozygous individuals had persistent hypercholanemia (P = 5.8 × 10–29). Exome sequencing 
excluded the involvement of other BA metabolism-associated genes in the hypercholanemia. Although 
asymptomatic, all individuals had low vitamin D levels. Of six adults that were subjected to bone 
mineral density analysis, three presented with osteoporosis/osteopenia. Sex hormones and blood 
lipids were deviated in all subjects. Homozygosity of p.Ser267Phe in SLC10A1 is associated with 
asymptomatic hypercholanemia. Individuals with homozygous p.Ser267Phe in SLC10A1 are prone to 
vitamin D deficiency, deviated sex hormones and blood lipids. Surveillance of these parameters may 
also be needed in patients treated with drugs targeting NTCP.
Bile acids (BAs) are synthesized from, and thereby regulate the levels of, cholesterol, which is the parent molecule 
of steroid hormones including sex hormones and adrenocortical hormones. BAs are essential for the absorption 
of lipids and lipid-soluble nutrients from the intestine1.
Sodium-taurocholate cotransporting polypeptide (NTCP), which is encoded by the SLC10A1 gene (solute 
carrier family 10 member 1; GenBank accession no. 6554), transports conjugated BAs and, to a less extent, uncon-
jugated BAs into hepatocytes from the plasma. NTCP has recently been identified as a hepatocellular receptor for 
hepatitis B virus (HBV) and hepatitis D virus (HDV)2. It also transports multiple drugs into hepatocytes, where 
they are metabolized3. Hence, NTCP is a target, or one of the targets, for several FDA-approved drugs3, including 
ezetimibe4 (for lowering blood lipids) and fusidic acid5 (antibacterial infection) used in Europe and Australia, as 
well as drugs that are currently in clinical trials, such as myrcludex B (anti-HBV/HDV infection)6.
It has been known that mutations in at least 10 genes involved in BA metabolism can cause serious dis-
eases associated with hypercholanemia (such as progressive intrahepatic cholestasis) (Online Mendelian 
Inheritance in Man, OMIM http://www.ncbi.nlm.nih.gov/omim and literature7). However, whether muta-
tions in SLC10A1 cause any clear phenotype has been a riddle8, 9. To date there are only four cases with 
deleterious mutations in SLC10A1 have been reported. One paper reported a patient with conjugated hyper-
cholanemia, hypotonia, growth retardation, and cognitive deficiency, who was homozygous for a p.Ar-
g252His mutation in SLC10A18. However, because the genetic analysis in this case was restricted to SLC10A1, 
the causal gene for the patient’s phenotypes is still open for investigation. The p.Ser267Phe mutation in 
SLC10A1 (rs2296651) is one of the most prevalent deleterious variations in East Asia among genes that are 
involved in BA metabolism, with an allele frequency of 8–12% in individuals in Southern China (http://
browser.1000genomes.org/Homo_sapiens/Variation/Population?db=core;r=14:70244693–70245693;v=rs
2296651;vdb=variation;vf=1673765). This mutation has also been identified in African and Latino popu-
lations (http://exac.broadinstitute.org/variant/14-70245193-G-A). In vitro experiments have shown that the 
p.Ser267Phe mutation loses most of its function of bile acid uptake and the ability to support HBV or HDV 
infection10–12. Another paper13 reported a pediatric patient who was homozygous for a p.Ser267Phe muta-
tion in SLC10A1 and had increased blood BA levels. However, this case had complications of liver disease 
and dermatitis, and the infant was delivered by cesarean section due to entanglement of the umbilical cord. 
These complications make it difficult to interpret the medical consequence of the mutation p.Ser267Phe 
in SLC10A1. Very recently, the fourth single case was reported, in whom the heterozygous mutations of 
p.Ser267Phe and the truncating mutation p.Ser206Profs*12 in SLC10A1 were identified. Apart from hyper-
cholanemia, the clinical condition of this case raised the question whether NTCP deficiency is linked to 
premature loss of fetus14.
To unravel the clinical phenotypes and to investigate the medical consequences of the p.Ser267Phe mutation 
in SLC10A1, we have identified eight individuals with homozygous p.Ser267Phe mutation in SLC10A1. We per-
formed in-depth medical investigations and exome sequencing in the homozygous individuals, and compared 
their BA levels with 170 wild-type and 107 heterozygous healthy individuals. Here we report our findings and 
their clinical implications.
Materials and Methods
Identification of individuals with homozygous p.Ser267Phe mutation in SLC10A1 and recruit-
ment of the cohort. During routine employer-sponsored health assessments, in which testing for total 
serum BAs (tsBAs) was included, two individuals (individuals 1 and 2) had higher levels of tsBAs than the 
hospital normal range in 2009 and 2014 respectively (Fig. 1a). The two individuals were asymptomatic. Our 
detailed medical investigations excluded all the causes of hypercholanemia that were known at the time, includ-
ing viral hepatitis, obstruction of biliary tract, toxic factor, medication factor, autoimmune liver disease, alco-
holic liver disease, fatty liver, liver cirrhosis, liver fibrosis and gastrointestinal diseases. As SLC10A1 was a gene 
for which we did not know whether mutations cause any phenotype, we sequenced the gene and found that 
both individuals were homozygous p.Ser267Phe mutations. To further investigate the medical significance of 
this mutation, we started to recruit individuals who are homozygous p.Ser267Phe in SLC10A1 from the Third 
Affiliate Hospital, Sun Yat-sen University, Southern China, in 2014. Our criteria were that individuals must be 
homozygous p.Ser267Phe in SLC10A1 and have excluded all the known conditions that may cause increased 
blood tsBAs; must not bear any other predicted deleterious mutations by SIFT (http://sift.jcvi.org/) among 
variations reported in the 1000 Genome Project (http://browser.1000genomes.org/Homo_sapiens/Search/
Results?site=ensembl&q=SLC10A1) and literature15, 16 (Supplementary Table S1) on SLC10A1; must have nor-
mal renal and liver function; must be unrelated to any other individuals in the cohort; and must not be on 
NTCP-targeting or interacting drugs (consecutive samples, June 2014–April 2016). We also recruited healthy 
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and unrelated individuals who were either heterozygous or wild-type for p.Ser267Phe and did not bear any 
other deleterious mutations in SLC10A1 as mentioned for the homozygous individuals from the Physical Checks 
Department (consecutive, February 2015–April 2016 for heterozygous and January 2016–April 2016 for wild-
type individuals). In total we recruited 285 individuals, including 8 individuals who were homozygous for the 
p.Ser67Phe mutation (Table 1), 107 healthy heterozygous individuals, and 170 healthy wild-type individuals 
(Supplementary Table S2). tsBAs were measured in all the individuals. We performed in-depth medical exami-
nations of the homozygous individuals, traced all their available medical records, and followed them up for 8–90 
months (Fig. 1a, Table 1).
Written informed consent was obtained from all participants. The study was approved by the Ethical 
Committee for Human Study, Sun Yat-sen University, and the Principles in the Declaration of Helsinki were 
followed.
Clinical laboratory investigations. Serum from the homozygous, heterozygous, and wild-type individuals 
was collected in the morning after at least 8 hours of fasting. The initial and follow-up tsBAs measurements were 
conducted in the hospital laboratory by the enzyme circle method using a Total Bile Acids Assay kit (Maccure, 
Chengdu, China) on a Hitachi 7180 automatic biochemical analyzer (Hitachi, Ibaraki, Japan). The tsBAs and six 
BA species were re-tested by the independent KingMed Diagnostics Lab (http://www.kingmed.com.cn) on a sep-
arate blood sample (individual 6 had three separate blood collections and tests) using the enzyme circle method 
and a Total Bile Acid Reagent Kit (Dongou, Wenzhou, China) on a Roche P800 automatic biochemical analyzer 
(Roche, Mannheim, Germany). Liquid chromatography-tandem mass spectrometry analysis was used to measure 
six species of BAs—taurodeoxycholic acid (TDCA), glycodeoxycholic acid (GDCA), cholic acid (CA), deoxy-
cholic acid (DCA), chenodeoxycholic acid (CDCA), and ursodeoxycholic acid (UDCA) on a Triple Quad 5500 
mass spectrometry (AB Sciex, California, USA) using the respective reagents (Sigma-Aldrich, Missouri, USA 
and C/D/N Isotopes Inc, Pointe-Claire, Canada) as previously reported17. Blood lipids, sex and adrenocortical 
hormones, and vitamin A and D levels of the homozygous individuals were measured by the hospital laboratory 
or the KingMed Diagnostics Lab (Supplementary Tables S3 and 4). Bone density was measured by dual energy 
X-ray absorptiometry (DXA, Discovery DXA System, Hologic Inc, Bedford, USA).
Sequencing and genotyping. Sanger sequencing was performed to genotype p.Ser267Phe in DNA 
extracted from blood. We also used Sanger sequencing to exclude all other mutations in SLC10A1 that are pre-
dicted to be deleterious by SIFT among the Chinese in the 1000 Genome Project and in two recent reports15, 16  
in the homozygous, heterozygous, and wild-type individuals in DNA extracted from blood (Supplementary 
Table S1). We also used Sanger sequencing to genotype the available parents of individuals 4 and 8. To exclude 
mosaicism, p.Ser267Phe was also sequenced from buccal samples of the homozygous individuals by Sanger 
sequencing.
To exclude possible contribution by other BA metabolism-associated genes to the hyperchalonemia, exome 
sequencing was performed on the Illumina and Proton platforms in the eight homozygous individuals (NCBI 
accession codes SRA438551; Supplementary Tables S5–7, text page 7–10, Supplementary Materials). We selected 
all of the genes known to cause hypercholanemia and genes coding for BA transporters in enterohepatic circu-
lation in OMIM and in the literature7 (18 genes, Supplementary Table S8), and 48 other genes involved in BA 
metabolism in OMIM and in the literature1, 7, 18 (Supplementary Table S8). We retrieved and compared all the 
Figure 1. Levels of total serum bile acids (tsBAs) tested at the hospital lab and the Kingmed Diagnostics lab.  
(a) Scatter plots of tsBAs among the eight individuals who had a homozygous p.Ser267Phe genotype in SLC10A1 
tested at the hospital lab. All tests were performed on serum from blood taken first thing in the morning after 
at least 8 hours of fasting. Red dot: individual 1, light blue: individual 2, dark blue: individual 3, light purple: 
individual 4, yellow: individual 5, dark green: individual 6, brown: individual 7, and dark purple: individual 8. 
The light green area shows the normal range for total serum bile acids (0–14 μmol/L) according to the hospital 
laboratory standards. (b) Boxplot of tsBAs among the eight individuals who had a homozygous p.Ser267Phe 
genotype in SLC10A1 according to the Kingmed Diagnostics Lab measurements. The boxplot shows the 
median, range, and inter-quartile range of tsBAs levels across these individuals.
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 9214  | DOI:10.1038/s41598-017-07012-2
variations in the 66 genes with minor allele frequencies lower than 30% among Eastern Asian/Chinese (http://
browser.1000genomes.org/Homo_sapiens) in the eight homozygous individuals (Supplementary Table S8).
To examine whether there is population stratification in the cohort (170 wild-type individuals, 107 
p.Ser267Phe heterozygous individuals, and 8 p.Ser267Phe homozygous individuals), we genotyped 21 
ancestry-informative markers (AIMs) in all samples in the three groups as previously reported (Supplementary 
Table S9)19 and designed a statistical test based on random sampling and using the strategy as we previously 
reported (text page 10–11, Supplementary Materials)20, 21.
Statistical analyses. We performed separate linear regressions for each of the six BA species and tsBAs as 
dependent variables and on the p.Ser267Phe genotypes as an independent variable using the R software package 
(http://www.r-project.org) on values obtained from the KingMed Diagnostics Lab. For all statistical regression 
analyses we normalized each of the bile acids using a log-transform, since the raw data for each was left-skewed. 
For each of the BA phenotypes we explored regressions on p.Ser267Phe under both recessive and additive models. 
All regressions were adjusted for age and gender. For the single individual (individual 6) with three measurements 
of each bile acid, we used their average values in the regressions. Statistical significance was ascribed according 
to a Bonferroni P-value threshold, which was adjusted for the total number of BA phenotypes that were tested 
and for the use of two genetic models (i.e., our threshold for declaring significance was P = 0.05/14 = 0.0036). The 
effect estimates from our linear regressions are interpreted as the mean change in log-bile acid associated with an 
extra copy of the p.Ser267Phe mutation under additive models, or with the homozygous genotype under recessive 
models. Under both models, a negative effect indicates the mutation is associated with a reduction in the bile acid, 
and a positive effect is associated with an increase in tsBAs or BA species.
Data availability statement. The raw data of the Illumina and Proton sequence reads of the whole exome 
sequence in the 8 individuals who are homozygous p.Ser267Phe in SLC10A1 have been deposited in the NCBI 
Sequence Read Archive, accession codes SRA438551.
Results
The homozygous p.Ser267Phe mutation in SLC10A1 is associated with hypercholanemia. All 
tsBAs tests that were performed in the hospital laboratory showed consistent hypercholanemia in all homozygous 
individuals (Fig. 1a). Moreover, all heterozygous and wild-type individuals were normocholanemic. The hospital 
measurement was confirmed by the analyses of the KingMed Diagnostics Lab, where tsBAs and 6 species of BAs 
were also measured in another blood collection (Table 2, Supplementary Table S2). The median of tsBAs was 
3.63 times the maximal reference of the KingMed Diagnostics Lab (Fig. 1b). Under both models, the recessive 
and additive genetic models, tsBAs, and two species of conjugated BAs—TDCA and GDCA—were significantly 
elevated (Under recessive genetic model P = 5.8 × 10−29, 2.4 × 10−14, 2.9 × 10−8, respectively; Under additive 
genetic model P = 1.0 × 10−25, 2.6 × 10−11, 1.1 × 10−8, respectively; Table 2). One species of unconjugated BAs—
CA—was also moderately increased (Under recessive genetic model P = 4.2 × 10−4; Under additive genetic model 
P = 1.4 × 10−5; Table 2). Analysis using the additive model also showed a moderate increase in the unconjugated 
DCA (P = 0.0013, Table 2).
Our Sequenom assay revealed no population stratification among the homozygous, heterozygous, and 
wild-type individuals, and the 21 ancestral informative markers were within the Hardy-Weinberg equilibrium 
(Fig. S1, Supplementary Table S9 and text page 10–11, Supplementary Materials).
These results demonstrated that homozygosity for p.Ser267Phe was associated with hypercholanemia made 
up of conjugated BAs, including TDCA, GDCA, and to a less extent, unconjugated CA.
Exome sequencing excluded the involvement of other BA metabolism-associated 
genes. Our exome sequencing detected a total of 23 variations in the 66 genes involved in BA metabolism 
in the homozygous individuals, besides p.Ser267Phe in SLC10A1 (Supplementary Table S8). Among the 23 
variations, 5 were predicted to be deleterious by SIFT. Individual 1 carried the heterozygous mutation p.Val-
174Ala in SLCO1B1 (solute carrier organic anion transporter family member 1B1); individual 4, 5, and 8 carried 
a heterozygous mutation p.Arg918His in MYO5B (myosin VB) (Supplementary Table S8); individual 1 and 3 
carried a heterozygous mutation p.Val186Phe in AMACR (alpha-methylacyl-CoA racemase); individual 7 had 
a heterozygous mutation p.Arg35Trp in ACOX2 (acyl-CoA oxidase 2); and individual 8 had a heterozygous 
Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 6 Individual 7 Individual 8
Sex Male Female Male Male Female Male Female Female
Age (years) 48 41 64 7 48 39 29 22
Menopausal age N/A* N/A N/A N/A 46 N/A N/A N/A
Occupation Medical Specialist Medical Specialist Farmer Student Cleaner Businessman Nurse Medical Student
Body mass index 26.2 20.0 23.4 14.5 (−0.9 SD)§ 20.1 25.9 17.4 19.7
Follow up (months) 90 30.5 21 25 13 10 8 8
Number of children 1 1 4 N/A 2 1 1 N/A
Table 1. Clinical and Demographic Data of the Individuals Who Are Homozygous for p.Ser267Phe in 
SLC10A1. *N/A: not applicable. §The normal body mass index range according to Chinese standards for 
individual 4 (7 years and 9 months old) is 13.0–20.623.
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mutation p.Val61Phe in FAH (fumarylacetoacetate hydrolase) (Supplementary Table S8). However, as the five 
genes are recessive, these heterozygous variations are unlikely to be the cause of their hypercholanemia. In 
contrast, each and all of the hypercholanemic individuals were homozygous for p.Ser267Phe in SLC10A1 
(Supplementary Table S8). This indicates that homozygosity of p.Ser267Phe in SLC10A1 is the likely cause of 
their hypercholanemia.
Sanger sequencing of buccal swabs produced the same results in p.Ser267Phe of SLC10A1 as the blood sam-
ples in all homozygous individuals. The available parents of individuals 4 and 8 were heterozygous p.Ser267Phe 
carriers. These results imply that homozygous p.Ser267Phe mutation likely originated in the germline and not 
through mosaicism.
The homozygous p.Ser267Phe mutation in SLC10A1 is associated with low vitamin D levels 
and differences in steroid hormones and blood lipids. All of the homozygous individuals were asymp-
tomatic. Our in-depth medical examinations showed that all of the individuals who were homozygous for the 
p.Ser267Phe mutation had normal liver and renal function and normal bilirubin levels. Their medical history 
showed that they did not have jaundice, pruritus, liver disease, or any of the conditions known to cause hyper-
cholanemia. However vitamin D levels were reduced in all individuals relative to the preferred range (Table 3)22. 
Osteoporosis or osteopenia was diagnosed in 3 of the 6 adults who consented to testing. But none had rickets, 
osteomalacia, a fracture, or back or joint pain. Owing to difficulties in assessing bone density in children, we did 
not classify individual 4, the 7-year-old boy, into any category (Table 4). Various sex hormones in the homozy-
gous individuals were deviated when compared with the Chinese normal range, but all homozygous adults had 
well-developed secondary sexual characteristics and were fertile (Table 1 and Supplementary Table S10). Various 
blood lipids also deviated from the normal range (Supplementary Table S11), and 24-hour urinary free cortisol 
levels were increased in individuals 1 and 7 (Table 3). Levels of vitamin A and aldosterone, and bleeding and 
coagulation times were normal in all individuals (Table 3, Supplementary Table S12). And other biochemistry and 
blood cell analysis were normal in all homozygous individuals (Supplementary Table S13).
Recessive genetic model% Additive genetic model
Effect§ 95% CI P-Value Effect 95% CI P-Value
tsBAs 2.84 (2.39, 3.28) 5.8 × 10−29 0.84 (0.70, 0.99) 1.0 × 10−25
TDCA 2.56 (1.93, 3.18) 2.4 × 10−14 0.71 (0.51, 0.91) 2.6 × 10−11
GDCA 2.87 (1.88, 3.86) 2.9 × 10−8 0.92 (0.61, 1.23) 1.1 × 10−8
CA 1.60 (0.72, 2.48) 4.2 × 10−4 0.61 (0.34, 0.89) 1.4 × 10−5
DCA 1.10 (0.17, 2.04) 0.021 0.48 (0.19, 0.77) 0.0013
CDCA 0.72 (−0.09, 1.53) 0.083 0.20 (−0.06, 0.45) 0.13
UDCA 0.55 (−0.33, 1.43) 0.22 0.00 (−0.28, 0.27) 0.99
Table 2. Statistical analyses of total serum bile acids (tsBAs) and six BA species for association with 
p.Ser267Phe genotype in SLC10A1#. #tsBAs: total serum bile acids. TDCA: taurodeoxycholic acid. GDCA: 
glycodeoxycholic acid. CA: cholic acid. DCA: deoxycholic acid. CDCA: chenodeoxycholic acid. UDCA: 
ursodeoxycholic acid. CI: confidence interval. The P-values were obtained from separate linear regressions 
for each log-bile acid (BA) per genotype and for the total serum BAs (tsBAs), adjusted for age and gender. 
Our threshold for declaring significance is P = 0.05/14 = 0.0036. %Recessive genetic model: for these linear 
regressions, the wild-type and heterozygous individuals were pooled and compared to the homozygous 
individuals. §Mean change in log-bile acid associated with having the homozygous mutation under the recessive 
models, or with each extra mutation under the additive models. Under both models a negative effect indicates 
the mutation is associated with a reduction in the bile acid, and a positive effect is an increase in tsBAs or BA 
species.
Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 6 Individual 7 Individual 8
25-hydroxyvitamin D§ (preferred range: 75.00–150.00) (nmol/L)
54.00 28.00/30.00/25.00 76.00/56.00 44.00/63.00/46.00 48.00 42.00 53.00 40.00
Cortisol (normal range: 118.60–618.00) (at 8:00 am) (nmol/L)
208.22 424.31 495.20/384.25 264.37 213.10 392.63 184.11 259.67
24-hour Urinary Free Cortisol*(normal range: 3–8y†, 1.40–20.00; ≥18 y†, 3.50–45.00) (μg/24 h)
46.40 22.30 19.70 14.90 20.10 15.50 77.00 15.40
Aldosterone (normal range: 40.00–310.00) (orthostatic) (pg/mL)
140.56 169.74 150.33 187.08 178.18 192.49 109.70 163.21
Table 3. Vitamin D and adrenocortical hormones (cortisol and aldosterone) in individuals who are 
homozygous for p.Ser267Phe in SLC10A1#. #Forward slash (/) distinguishes tests that were separately 
performed. §Figures that deviate from the preferred range are in bold italics and are underlined. *Figures that 
deviate from the normal range are in bold italics and are underlined. †y: years.
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Discussion
We have identified a new type of hypercholanemia that is associated with homozygosity for the p.Ser267Phe 
mutation in SLC10A1. This type of hypercholanemia is different from the previously recognized hypercholanemia 
in that it is associated with a different gene, and the individuals were all asymptomatic. It is different from the 
single reported case of the homozygous p.Arg252His mutation in SLC10A1, in whom neurological and devel-
opmental delay were present8, besides conjugated hypercholanemia. The germline origin of the mutation and 
the age range of our homozygous group suggest that this type of hypercholanemia is likely to begin early in 
life. The allele frequency of this mutation varies in different populations, with the highest incidence occurring 
in Southern China (8% and 12% in Chinese Han and Dai respectively) and Vietnam (11%) (http://brows-
er.1000genomes.org/Homo_sapiens/Variation/Population?db=core;r=14:70244693–70245693;v=rs2296651; 
vdb=variation;vf=1673765). Taking these observations together, we propose that this “hidden” hypercholane-
mia affects 0.64% of the Southern Han, 1.44% of the Dai Chinese population, and 1.21% of the Vietnamese 
population.
The most notable finding in the homozygous individuals was the increase in conjugated and unconjugated 
serum BA levels. We suggest that this finding is most likely due to reduced BA transport from the portal circula-
tion into hepatocytes. This supports the hypothesis that the physiological function of the enterohepatic circula-
tion is not only to recycle BAs but also to clear BAs from the circulation to achieve homeostasis9. Alternatively, 
the liver may synthesize increased levels of BAs to compensate for the reduced enterohepatic recirculation in the 
homozygous carriers. As NTCP also transports unconjugated BAs, the increase of the unconjugated BA species 
observed in our study is not surprising.
BAs have detergent properties and excessive concentrations of them are thought to be toxic to the liver and 
other tissues, including vascular endothelium23. However, the results of our in-depth medical investigations seem 
to challenge this view, at least for vasculature at the observed blood BA levels, as our homozygous individuals all 
exhibited elevated tsBAs levels but had no liver and vascular damage or other apparent tissue damages.
Another consistent finding in our study cohort was the reduced vitamin D level in homozygous individ-
uals. We observed reduced vitamin D levels in all homozygous individuals and osteoporosis or osteopenia in 
3 of 6 adult homozygous individuals that were tested, which is consistent with findings from the single case 
study of the individual with the homozygous p.Arg252His mutation8 and the individual with homozygous 
p.Ser267Phe mutation13. These results suggest that the homozygous carriers are prone to vitamin D deficiency. 
Its level and bone density should be monitored, as interventions may be necessary to mitigate any poten-
tial effects in the homozygous individuals. This may also be appropriate for patients who undergo long-term 
NTCP-targeted therapies. All homozygous individuals were asymptomatic and had excluded gastrointestinal 
diseases, there was no evidence to support that low vitamin D level are the consequence of intestinal malab-
sorption. The p.Ser267Phe mutation loses most of its function of bile acid uptake in in vitro experiments 10, 11. 
Hypercholanemia may lead to lower level of bile acids in the intestine in all homozygous individuals. As bile 
acids play roles in emulsification and absorption of fat and fat-soluble vitamins, insufficient bile acids in the 
intestine could lead to fat-soluble vitamin D deficiency in these homozygous individuals. And studies on the 
related mechanisms are underway.
The deviations of levels of sex hormones, blood lipids, and urinary free cortisol seemed to show no consistent 
patterns in the homozygous individuals. This may be due to an adaptive response to chronic hypercholanemia, 
wherein the expression levels of multiple genes involved in metabolism of BAs, blood lipids and steroid hor-
mones are altered. Whether these deviations are specifically associated with this novel form of hypercholanemia 
described here, and whether they are clinically significant, will require further investigation and longer follow-up. 
Overall results from our study demonstrate a remarkable genomic resilience and seemed reassuring for the new 
NTCP-targeting drugs6 that show strong potential for the treatment of hepatitis B and D.
The limitation of this study is the sample size. As the homozygous individuals are asymptomatic, it has taken 
considerable effort to recruit eight individuals.
In this study we report the identification of a new type of hypercholanemia. And our research about homozy-
gous p.Ser267Phe individuals has implications for personalized medicine. The results from our study suggest 
that SLC10A1 mutations should be screened for in individuals with asymptomatic hypercholanemia. We also 
Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 6 Individual 7 Individual 8
Lumbar vertebra (g/cm2) Did not consent 1.20 (L1–4) 0.85 (L2-3) 0.57 (L1-4) 0.79 (L2-4) 0.75 (L1-4) 0.97 (L1-4) 0.92 (L1-4)
T-Score/Z-Score 1.3/1.5 −2.3/−1.6 N/A†/0.4 −2.6/−2.0 −3.1/−3.0 −0.7/−0.7 −1.2/−1.0
Femoral neck (g/cm2) Did not consent 0.78 0.70 0.54 0.66 0.61 0.88 0.77
T-Score/Z-Score −0.6/−0.3 −1.7/−0.7 N/A/−1.4 −1.7/−1.1 −2.3/−1.9 0.3/0.3 −0.7/−0.7
Total hip (g/cm2) Did not consent 0.90 0.86 0.62 0.74 0.79 0.96 0.91
T-Score /Z-Score −0.4/−0.2 −1.2/−0.7 N/A/−0.7 −1.7/−1.3 −1.6/−1.4 0.2/0.2 −0.3/−0.3
Diagnosis Normal Osteopenia Unclassified Osteoporosis Osteoporosis Normal Normal
Table 4. Bone mineral density of individuals who are homozygous for p.Ser267Phe in SLC10A1#,§. #Figures that 
deviate from the normal range are in bold italics and are underlined. §Dual energy X-ray absorptiometry (DXA) 
measurements were made on a Discovery DXA System (Hologic Inc, Bedford, USA). The WHO criteria for 
classification in adults: Male age ≥ 50 or post-menopausal phase women: Normal: T-scroe ≥ –1.0, Osteopenia: 
–2.5 < T-scroe < –1.0; Osteoporosis: T-scroe ≤ –2.5. Male Age < 50 or non-menopause women: Normal: 
Z-score > –2.0, Osteoporosis: Z-score ≤ −2.0. †N/A: not applicable.
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recommend that levels of vitamin D be monitored or supplemented, while bone density and sex hormones, cor-
tisol, and blood lipids should be carefully monitored in carriers who are homozygous p.Ser267Phe of SLC10A1 
and in patients who are undergoing long-term NTCP-targeted therapies, including the drugs that are currently in 
clinical trials, such as myrcludex B (anti-HBV/HDV infection)6.
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